AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively, exhibiting little activity outside the AGC kinase family.

3CAI is a potent allosteric and specific AKT inhibitor, which exerts efficacy in vitro and in vivo.

Deguelin is a naturally occuring Akt inhibitor purified from the herbs of Derris robusta, which downregulates Akt phosphorylation and shows anticancer effect.

SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

ARQ 092 is a pan-Akt inhibitor with IC50 values of 5nM, 4.5nM and 16nM for Akt1, Akt2 and Akt3, respectively, through blocking membrane translocation of inactive AKT and even dephosphorylating the membrane-associated active form.

PRE-084 HCl is a high affinity, selective σ1 agonist, has an IC50 of 44 nM in the sigma receptor assay.

MSC2363318A, also known as M2698, is an orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity.

Fluorofenidone attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and ECM deposition via the PI3K/Akt signalling pathway, suggesting AKF-PD is a potential novel therapeutic agent against renal fibrosis.

Oridonin is an antitumor agent, a diterpenoid purified from Rabdosia rubescens. Oridonin interacts with the cysteine 279 of NLRP3 NACHT domain through a covalent bond, abolishes NLRP3-NEK7 interaction, and inhibits consequent activation of NLRP3 inflammasome.